Search research articles
Contact Us
Filters
Showing results (91-100 of 173) with videos related to
Page
of 18
Sort By:
American Journal of Physiology. Heart and Circulatory Physiology
|
October 26, 2010
Knockout of insulin receptors in cardiomyocytes attenuates coronary arterial dysfunction induced by pressure overload
J David Symons, Ping Hu, Ying Yang, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
May 29, 2025
Device Therapy for Heart Failure With Preserved Ejection Fraction: The Problem, the Mechanism, the Device, the Trial
Scott M Lilly, Firas Zahr, Mark N Belkin, et al.
Cell Metabolism
|
December 2, 2008
Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1
Ningning Wang, Guangrui Yang, Zhanjun Jia, et al.
Journal of Molecular and Cellular Cardiology
|
May 26, 2015
Antioxidant treatment normalizes mitochondrial energetics and myocardial insulin sensitivity independently of changes in systemic metabolic homeostasis in a mouse model of the metabolic syndrome
Olesya Ilkun, Nicole Wilde, Joseph Tuinei, et al.
European Journal of Heart Failure
|
June 26, 2024
A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial
Dalane W Kitzman, Gregory D Lewis, Ambarish Pandey, et al.
Molecular Endocrinology (Baltimore, Md.)
|
September 20, 2008
Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy
Jaetaek Kim, Adam R Wende, Sandra Sena, et al.
Endocrinology
|
September 8, 2007
Cardiac hypertrophy caused by peroxisome proliferator- activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling
Sandra Sena, Isaac R Rasmussen, Adam R Wende, et al.
Cardiovascular Research
|
June 14, 2013
Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy
Sankaranarayanan Kannan, Vasanthi R Muthusamy, Kevin J Whitehead, et al.
Journal of the American College of Cardiology
|
September 3, 2025
Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis
Milton Packer, Michael R Zile, Christopher M Kramer, et al.
Journal of the American College of Cardiology
|
November 3, 2018
Lifestyle Modifications for Preventing and Treating Heart Failure
Monica Aggarwal, Biykem Bozkurt, Gurusher Panjrath, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 173) with videos related to
Sort By:
Page
of 18
American Journal of Physiology. Heart and Circulatory Physiology
|
October 26, 2010
Knockout of insulin receptors in cardiomyocytes attenuates coronary arterial dysfunction induced by pressure overload
J David Symons, Ping Hu, Ying Yang, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
May 29, 2025
Device Therapy for Heart Failure With Preserved Ejection Fraction: The Problem, the Mechanism, the Device, the Trial
Scott M Lilly, Firas Zahr, Mark N Belkin, et al.
Cell Metabolism
|
December 2, 2008
Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1
Ningning Wang, Guangrui Yang, Zhanjun Jia, et al.
Journal of Molecular and Cellular Cardiology
|
May 26, 2015
Antioxidant treatment normalizes mitochondrial energetics and myocardial insulin sensitivity independently of changes in systemic metabolic homeostasis in a mouse model of the metabolic syndrome
Olesya Ilkun, Nicole Wilde, Joseph Tuinei, et al.
European Journal of Heart Failure
|
June 26, 2024
A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial
Dalane W Kitzman, Gregory D Lewis, Ambarish Pandey, et al.
Molecular Endocrinology (Baltimore, Md.)
|
September 20, 2008
Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy
Jaetaek Kim, Adam R Wende, Sandra Sena, et al.
Endocrinology
|
September 8, 2007
Cardiac hypertrophy caused by peroxisome proliferator- activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling
Sandra Sena, Isaac R Rasmussen, Adam R Wende, et al.
Cardiovascular Research
|
June 14, 2013
Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy
Sankaranarayanan Kannan, Vasanthi R Muthusamy, Kevin J Whitehead, et al.
Journal of the American College of Cardiology
|
September 3, 2025
Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis
Milton Packer, Michael R Zile, Christopher M Kramer, et al.
Journal of the American College of Cardiology
|
November 3, 2018
Lifestyle Modifications for Preventing and Treating Heart Failure
Monica Aggarwal, Biykem Bozkurt, Gurusher Panjrath, et al.
Page
of 18